NBS NeoStem, Inc. Announces the Redemption of the

New Post Public Reply Private Reply Replies (0) Message Board

Oct 17, 2012 at 9:44 AM

NBS >>> NeoStem, Inc. Announces the Redemption of the Outstanding 7% Series E Preferred Stock

2012-10-17 07:30 ET - News Release

NEW YORK, Oct. 17, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy market, today announced that it will redeem all outstanding shares of its Series E 7% Senior Convertible Preferred Stock ("Series E Preferred Stock").

On October 10, 2012, the Company gave notice to its Series E Preferred Stockholders that it is redeeming all of the outstanding shares of Series E Preferred Stock for an aggregate redemption price of $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010.

"We are pleased that we have been able to redeem this $10 million investment in full over a two year period. Equal to our focus on cell therapy product development and expanding our PCT contract development and manufacturing operations, we are committed to improving our balance sheet. Through the redemption of the Series E Preferred Stock, we will remove a significant overhang and simplify NeoStem's capital structure. The redemption of the Series E Preferred Stock is another example of a step taken by us to improve Common Stockholder value," said Dr. Robin Smith, Chairman and CEO of NeoStem. "We look forward to continued execution on our near term business strategy, including the forthcoming closing of the divestiture of our Erye China pharmaceutical subsidiary."

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com.

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing ("CDMO") business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cooper's Heat Pump Campaign Fuels Denver's Community

How Heat Pumps Meet Philanthropy in Denver Alright, let me lay it out for you—a story as much about ingenuity as generosity. Cooper Heating & Cooling, donning their ‘Cooper Green Team’ capes, just wrapped up one heck of a community-driven campaign. They dropped a cool $5,000 into the coffers of We Don't Waste, a Denver nonprofit focused on food recovery. This...

CVRx Faces Legal Storm: Class Action Threat Looms

Cracks in the Foundation: CVRx's Turmoil Let me tell you, it's not every day you see a company drop a bombshell on investors like CVRx did, shaking up the ole portfolio right down to its socks. NASDAQ:CVRX has found itself embroiled in a class action lawsuit courtesy of a knotty mix of legal woes, unplanned revenue slashes, and executive shake-ups. A few short years ago,...

RAI's TrustX Lab Unveils AI Assurance Framework

Pushing the Envelope on AI Control Alright, AI wonks, the Responsible AI Institute just introduced a new sheriff in town. It's called the TrustX Assurance Lab, and it was rolled out during RAISE 2026. We're talking about an independent setup designed to answer whether autonomous AI can stay within its limits. Who's involved? A lot of brainpower from member organizations...

Shukla MD's New Concierge Program Boosts Patient Care

Shifting the Healthcare Paradigm Imagine a healthcare world where doctors actually have the time to listen and engage with you beyond just scribbling notes in haste. That's what's brewing over in Westchester, where Dr. Rachana and Dr. Vaishalee Shukla are putting the old-school patient-doctor relationship front and center with their Hybrid Choice concierge program. Run...

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Capital Properties Faces Leadership Challenge Amid Health News

Leadership Takes an Unexpected Turn at Capital Properties When the helm of a ship faces turbulence, everyone's eyes turn to the captain. In the case of Capital Properties, Inc., their captain, Chairman, CEO and President Robert H. Eder, has hit a personal snag, diagnosed with cancer but determined to steer steady despite the storm brewing within. A Glance at Capital...

Meijer Team Gives Fuels Midwest Nonprofits: $3M Impact

Power to the Team: Meijer Makes Big Moves On any ordinary day, you'd see folks in Grand Rapids, Michigan, bustling about their routines, but today packs a different vibe. Meijer, the retailer that's been around the block a few times, is handing over a serious chunk of change to the tune of $3 million. This ain't just some half-hearted corporate stunt. Nope, this is the...

Graphy's EU-MDR Milestone: A New Era for Dental 3D Printing

TeraHarz Material Certification: A Step Forward The medical device world has its own Everest, and for Graphy Inc., scaling it means navigating the EU's toughened Medical Device Regulation. They’ve done just that for five of their TeraHarz materials, gearing up to snatch those shiny CE-MDR certificates soon. For anyone keeping tabs on the dental market, that’s a big...

Outdoor Learning: Sparking Preschool Curiosity Weekly

Rekindling Curiosity in Nature’s Classroom With autumn’s crisp air rolling into Greenville, families have a golden opportunity to take learning beyond the traditional classroom. Archway Academy sees the beauty of this season as a sprawling classroom, one that doesn't confine young minds and bodies. For those of us focused more on dollars and sense, the financial...

Budget Airlines' Woes Reveal Travel Insurance Pitfalls

A Turbulent Ride for Travelers Man, it seems like the skies aren't so friendly nowadays, especially if you've got your hard-earned dollars wrapped up in a flight with a budget airline like Spirit or JetBlue. Here's the latest scoop: JetBlue's finances are under the microscope, and if you're planning to fly with them, you better become a travel insurance expert pronto. The...